VC-backed ImCheck Therapeutics raises $53m series-B

BPI France invested via its InnoBio 2 and Large Venture funds. Pfizer Ventures is the corporate venture arm of pharmaceutical giant Pfizer.

The co-leads were joined by new investors Wellington Partners, Agent Capital and Alexandria Venture Investments. Existing investors Life Sciences Partners (LSP), Gimv, Idinvest Partners, Kurma Partners and Boehringer Ingelheim Venture Fund re-upped as part of the fresh round.

ImCheck will use the funds raised to finance the initial clinical trial for its news monoclonal antibody ICT01, further expand its pipeline of immunomodulators, and bring additional immuno-oncology antibody programmes into the clinic.

Previous funding
German venture capital house Boehringer Ingelheim Venture Fund led a €20m series-A round for the French business in 2017.

Kurma, Idinvest, Gimv and LSP also took part in the funding round. According to a statement at the time, Gimv provided a €5m equity ticket as part of the funding round.

Company
ImCheck is a biotech company developing a new antibody to activate gamma delta T-cells in a range of cancer indicators, and a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases.

The business span out from Marseille's Institut Paoli-Calmettes in 2015.

People
ImCheck Therapeutics – Pierre d'Epenoux (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• France
• Healthcare
• France
• Venture
• BPI France